Earlier this year, we were encouraged by the release of Health Canada’s final report regarding the legislative review of the Cannabis Act, in particular Recommendation 42, which validated the need to improve patient access to medical cannabis by allowing for dispensing from pharmacies; and Recommendation 46, which acknowledged the need for advancement of a regulatory pathway for CHPs.
The draft of proposed regulatory amendments does not support patient access to cannabis for medical or therapeutic purposes, nor does it address regulatory framework for cannabis health products (CHPs) containing cannabidiol. We anticipate further regulatory development in these areas and look forward to working with Health Canada to provide pharmacy’s perspective on ensuring Canadians can access these therapeutic products when they need them.